Linnea Burman, senior vice president and president of Medtronic (MDT) Neurovascular, discusses the recent acquisition of Scientia Vascular, Scientia’s innovative technology, how it fits in MDT’s current portfolio and MDT’s strategies for driving growth in Neurovascular in an interview with SmartTRAK.
To find out more, including MDT’s vision for neurovascular robotics, creating inflection points for success, targeting emerging markets, and what’s next regarding new products and research, click the video below to watch the full interview (32:09). For additional details, see the time-coded topics listed below, along with a link to download the complete transcript.
For more information on Scientia Vascular, see SmartTRAK’s June 2025 interview with Scientia Vascular CEO Rick Randall: Scientia Vascular: Innovating to Disrupt Stroke Care.
00:06 MDT’s recent acquisition of Scientia Vascular. How Scientia’s devices complement MDT’s portfolio. Scientia’s unique microfabrication technology, what differentiates it in the market, and how Scientia’s intellectual property may impact MDT’s R&D roadmap.
04:41 Robotics is heating up in neurovascular. What is MDT’s vision for neurovascular robotics? Looking at robotic technologies, expanding patient access, addressing specialty shortages. How Scientia’s technology fits within that vision.
08:38 Potential impact of the Scientia acquisition and integration on MDT’s revenue, particularly OUS, since MDT revenues have been affected by value-based procurement in China as well as the Pipeline Vantage recall. How MDT has been setting up the next inflection point in Neurovascular through talent, organic product development, acquisitions, and scaling manufacturing.
10:00 The story behind MDT’s Pipeline Vantage recall. How MDT used modeling and simulation to study Vantage, learn more about flow diversion and develop two new flow diverter products that are in the pipeline. What’s next in terms of surface modification?
13:00 MDT’s strategies for growth. MDTs’ five-year roadmap and the status of product development. New indications, including Onyx cSDH, migraine, headache, mergers and acquisitions, and expanding evidence/clinical research. Combining Neurovascular and Neuromodulation product development and the potential for addressing other indications using brain-computer interfaces, including endovascular vagal nerve stimulation for stroke recovery and other applications.
17:00 The market for middle meningeal artery MMA embolization (MMAe) and anticipated growth for MDT and the market, particularly given increasing competition. Access and reimbursement for MMAe. Discussion about cerebral venous disorders and MDT’s plans for product development and research in these emerging areas. The number of transverse sinus stenting cases performed annually.
20:56 What will drive and limit growth in the market for neurovascular over the next few years? How is the recent research evaluating mechanical thrombectomy for use in distal and medium vessel occlusions and the trends in the use of stent retrievers vs aspiration impacting the market and MDT Neurovascular.
23:45 MDT’s view of aspiration technology, including 088 catheters, cyclic aspiration and Scientia’s guidewires. Update on Artisse, commercial availability OUS, physician feedback and status of the US IDE study.
26:33 Status of initiatives involving AI and digital health, including different partnerships around the world, including Methinks, Brainomix. Using real-world evidence, modeling, simulation and imaging to size devices. Using the Co-Lab Platform as an upstream funnel for identifying promising companies and technologies.
29:50 Final thoughts. What’s next for MDT Neurovascular?
Click the button below to download the full transcript of "Medtronic: Creating Inflection Points in Neurovascular," Anne Staylor’s interview with Linnea Burman, SVP and President of Medtronic Neurovascular.
SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s proprietary methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services. If you would like a demo of what SmartTRAK has to offer and see how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.